Cat. No.: HY-N0288

Lycorine

24 Cited Publications

Avis client

Based on 24 publication(s) in Google Scholar

Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription. Lycorine is also a melanoma vasculogenic inhibitor. Lycorine can be used for the study of prostate cancer and metabolic diseases.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.98%
CAS No.: 476-28-8
Formule: C₁₆H₁₇NO₄
Masse moléculaire:287.31

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Lycorine Chemical Structure

CAS No.: 476-28-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (24)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Lycorine is a natural alkaloid extracted from the Amaryllidaceae plant. Lycorine is a potent and orally active SCAP inhibitor with a K_d value 15.24 nM. Lycorine downregulates the SCAP protein level without changing its transcription^[2]. Lycorine is also a melanoma vasculogenic inhibitor^[3]. Lycorine can be used for the study of prostate cancer and metabolic diseases^[2].

IC₅₀ & Target

Kd: 15.24 nM (SCAP)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human A2780 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
A-431	ED₅₀	1.3 μg/mL Compound: 2	Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
A549	GI₅₀	0.9 μM Compound: 1	Growth inhibition of pro-apoptotic stimuli-resistant human A549 cells after 72 hrs by MTT assay Growth inhibition of pro-apoptotic stimuli-resistant human A549 cells after 72 hrs by MTT assay	[PMID: 22019045]
A549	GI₅₀	3 μM Compound: 1	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 24393582]
A549	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
A549	IC₅₀	1.9 μM Compound: 14	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23190013]
A549	IC₅₀	2 μM Compound: lycorine	Growth inhibition of apoptosis-resistant human A549 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-resistant human A549 cells after 72 hrs by MTT assay	[PMID: 20415482]
A549	IC₅₀	4.2 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human A549 cells after 72 hrs by MTT colorimetric assay	[PMID: 20550100]
A549	IC₅₀	4.3 μM Compound: 1, lycorine	Growth inhibition of proapoptotic stimuli-resistant human A549 cells after 72 hrs by MTT assay Growth inhibition of proapoptotic stimuli-resistant human A549 cells after 72 hrs by MTT assay	[PMID: 19788245]
AGS	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human AGS cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human AGS cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
B16-F10	GI₅₀	2 μM Compound: 1	Growth inhibition of pro-apoptotic stimuli-sensitive mouse B16F10 cells after 72 hrs by MTT assay Growth inhibition of pro-apoptotic stimuli-sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 22019045]
B16-F10	GI₅₀	2.6 μM Compound: 1	Growth inhibition of mouse B16F10 cells by MTT assay Growth inhibition of mouse B16F10 cells by MTT assay	[PMID: 24393582]
B16-F10	IC₅₀	2 μM Compound: lycorine	Growth inhibition of apoptosis-sensitive mouse B16F10 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 20415482]
B16-F10	IC₅₀	6.3 μM Compound: 1	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT colorimetric assay	[PMID: 20550100]
B16-F10	IC₅₀	6.3 μM Compound: 1, lycorine	Growth inhibition of proapoptotic stimuli-sensitive mouse B16F10 cells after 72 hrs by MTT assay Growth inhibition of proapoptotic stimuli-sensitive mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 19788245]
BEAS-2B	IC₅₀	4.9 μM Compound: 14	Cytotoxicity against human BEAS2B cells after 48 hrs by MTT assay Cytotoxicity against human BEAS2B cells after 48 hrs by MTT assay	[PMID: 23190013]
BHK-21	CC₅₀	4.37 μM Compound: 8	cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay cytotoxicity against golden hamster BHK-21 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
BJ	IC₅₀	1.9 μM Compound: 2	Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay Cytotoxicity against human BJ cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
BT-549	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human BT-549 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
CCRF-CEM	IC₅₀	1.6 μM Compound: 2	Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay Cytotoxicity against human CEM cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
COLO 201	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human COLO201 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human COLO201 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
G-361	IC₅₀	5 μM Compound: 2	Cytotoxicity against human G361 cells after 72 hrs by Calcein AM assay Cytotoxicity against human G361 cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
HEK-293T	CC₅₀	1.044 μM Compound: 95	Cytotoxicity against human HEK293T cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HEK293T cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 37597436]
HeLa	IC₅₀	10.6 μM Compound: 2	Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay Cytotoxicity against human HeLa cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
HepG2	IC₅₀	3.7 μM Compound: 14	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23190013]
HL-60	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
HL-60	IC₅₀	1.6 μM Compound: 14	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23190013]
Hs 683	GI₅₀	0.9 μM Compound: 1	Growth inhibition of pro-apoptotic stimuli-sensitive human Hs683 cells after 72 hrs by MTT assay Growth inhibition of pro-apoptotic stimuli-sensitive human Hs683 cells after 72 hrs by MTT assay	[PMID: 22019045]
Hs 683	GI₅₀	2.1 μM Compound: 1	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 24393582]
Hs 683	IC₅₀	2 μM Compound: lycorine	Growth inhibition of apoptosis-sensitive human Hs 683 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-sensitive human Hs 683 cells after 72 hrs by MTT assay	[PMID: 20415482]
Hs 683	IC₅₀	6.7 μM Compound: 1, lycorine	Growth inhibition of proapoptotic stimuli-sensitive human Hs683 cells after 72 hrs by MTT assay Growth inhibition of proapoptotic stimuli-sensitive human Hs683 cells after 72 hrs by MTT assay	[PMID: 19788245]
Hs 683	IC₅₀	6.9 μM Compound: 1	Cytotoxicity against human Hs683 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human Hs683 cells after 72 hrs by MTT colorimetric assay	[PMID: 20550100]
HT-1080	ED₅₀	0.5 μg/mL Compound: 2	Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
HT-29	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
HT-29	IC₅₀	3.2 μM Compound: 14	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 23190013]
Huh-7	CC₅₀	0.834 μM Compound: 95	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37597436]
Huh-7	CC₅₀	66.12 μM Compound: GNF-Pf-4974	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	[PMID: 18579783]
Jurkat	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human Jurkat cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
K562	IC₅₀	2.3 μM Compound: 14	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 23190013]
K562	IC₅₀	3.6 μM Compound: 2	Cytotoxicity against human K562 cells after 72 hrs by Calcein AM assay Cytotoxicity against human K562 cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
KB	ED₅₀	0.3 μg/mL Compound: 2	Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
KB-V1	ED₅₀	0.4 μg/mL Compound: 2	Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
LLC-MK2	CC₅₀	3.81 μM Compound: 8	Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay Cytotoxicity against Rhesus macaque LLC-MK2 cells incubated for 72 hrs by MTT assay	[PMID: 32845145]
LNCaP	ED₅₀	0.5 μg/mL Compound: 2	Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
Macrophage	IC₅₀	2.5 μM Compound: 9	Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay Inhibition of LPS-induced NO production in ddY mouse macrophages after 20 hrs by Griess reagent assay	[PMID: 15270564]
MCF7	GI₅₀	10.9 μM Compound: 1	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 24393582]
MCF7	GI₅₀	4 μM Compound: 1	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 22019045]
MCF7	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
MCF7	IC₅₀	13 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay Cytotoxicity against human MCF7 cells after 72 hrs by Calcein AM assay	[PMID: 22921081]
MDA-MB-231	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
MDCK	CC₅₀	20.9 μM Compound: 24; AA1	Cytotoxicity against MDCK cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against MDCK cells incubated for 72 hrs by CCK-8 assay	[PMID: 38283223]
MOLT-4	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human MOLT-4 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
NCI-H1299	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
NHDF	IC₅₀	>100 μM Compound: 1, lycorine	Growth inhibition of human NHDF after 72 hrs by MTT assay Growth inhibition of human NHDF after 72 hrs by MTT assay	[PMID: 19788245]
NHDF	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human NHDF cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human NHDF cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
P388	ED₅₀	0.9 μg/mL Compound: 2	Cytotoxicity against mouse P388 cells after 3 days by sulforhodamine B assay Cytotoxicity against mouse P388 cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
PANC-1	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
PC-3	GI₅₀	4 μM Compound: 1	Growth inhibition of human PC3 cells after 72 hrs by MTT assay Growth inhibition of human PC3 cells after 72 hrs by MTT assay	[PMID: 22019045]
SAOS-2	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human SAOS-2 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human SAOS-2 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
SK-BR-3	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human SK-BR-3 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
SK-MEL	IC₅₀	8.4 μM Compound: 1	Cytotoxicity against human SK-MEL cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human SK-MEL cells after 72 hrs by MTT colorimetric assay	[PMID: 20550100]
SK-MEL-2	ED₅₀	1.6 μg/mL Compound: 2	Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
SK-MEL-28	GI₅₀	3.7 μM Compound: 1	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 24393582]
SK-MEL-28	GI₅₀	4 μM Compound: 1	Growth inhibition of pro-apoptotic stimuli-resistant human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of pro-apoptotic stimuli-resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 22019045]
SK-MEL-28	IC₅₀	2 μM Compound: lycorine	Growth inhibition of apoptosis-resistant human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 20415482]
SK-MEL-28	IC₅₀	8.5 μM Compound: 1, lycorine	Growth inhibition of proapoptotic stimuli-resistant human SK-MEL-28 cells after 72 hrs by MTT assay Growth inhibition of proapoptotic stimuli-resistant human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 19788245]
SW480	IC₅₀	0.3 μM Compound: Lycorine	Cytotoxicity against human SW480 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay Cytotoxicity against human SW480 cells assessed as cell growth inhibition incubated for 48 hrs by WST-1 assay	[PMID: 34536668]
T98G	GI₅₀	3 μM Compound: 1	Growth inhibition of pro-apoptotic stimuli-resistant human T98G cells after 72 hrs by MTT assay Growth inhibition of pro-apoptotic stimuli-resistant human T98G cells after 72 hrs by MTT assay	[PMID: 22019045]
T98G	GI₅₀	5.2 μM Compound: 1	Growth inhibition of human T98G cells by MTT assay Growth inhibition of human T98G cells by MTT assay	[PMID: 24393582]
U-373MG ATCC	ED₅₀	0.3 μg/mL Compound: 2	Cytotoxicity against human U373 cells after 3 days by sulforhodamine B assay Cytotoxicity against human U373 cells after 3 days by sulforhodamine B assay	[PMID: 8229016]
U-373MG ATCC	GI₅₀	3 μM Compound: 1	Growth inhibition of pro-apoptotic stimuli-resistant human U373 cells after 72 hrs by MTT assay Growth inhibition of pro-apoptotic stimuli-resistant human U373 cells after 72 hrs by MTT assay	[PMID: 22019045]
U-373MG ATCC	IC₅₀	2 μM Compound: lycorine	Growth inhibition of apoptosis-resistant human U373 cells after 72 hrs by MTT assay Growth inhibition of apoptosis-resistant human U373 cells after 72 hrs by MTT assay	[PMID: 20415482]
U-373MG ATCC	IC₅₀	7.6 μM Compound: 1	Cytotoxicity against human U373 cells after 72 hrs by MTT colorimetric assay Cytotoxicity against human U373 cells after 72 hrs by MTT colorimetric assay	[PMID: 20550100]
U-373MG ATCC	IC₅₀	7.6 μM Compound: 1, lycorine	Growth inhibition of proapoptotic stimuli-resistant human U373 cells after 72 hrs by MTT assay Growth inhibition of proapoptotic stimuli-resistant human U373 cells after 72 hrs by MTT assay	[PMID: 19788245]
Vero	CC₅₀	>1000 μM Compound: 95	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	[PMID: 37597436]
Vero	CC₅₀	21 μM Compound: 14	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 34274831]
Vero	IC₅₀	0.24 μg/mL Compound: 16	Antiviral activity against Dengue virus type 4 infected in african green monkey Vero cells after 6 days by plaque reduction assay Antiviral activity against Dengue virus type 4 infected in african green monkey Vero cells after 6 days by plaque reduction assay	[PMID: 1336040]
Vero	IC₅₀	0.28 μg/mL Compound: 16	Antiviral activity against Yellow fever virus Ashibi infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Yellow fever virus Ashibi infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 1336040]
Vero	IC₅₀	0.33 μg/mL Compound: 16	Antiviral activity against Japanese encephalitis virus Nakayama infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Japanese encephalitis virus Nakayama infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 1336040]
Vero	IC₅₀	0.5 μg/mL Compound: 16	Antiviral activity against Punta Toro virus Adames infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against Punta Toro virus Adames infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 1336040]
Vero	IC₅₀	0.93 μg/mL Compound: 16	Antiviral activity against Rift Valley fever virus infected in african green monkey Vero cells after 6 days by plaque reduction assay Antiviral activity against Rift Valley fever virus infected in african green monkey Vero cells after 6 days by plaque reduction assay	[PMID: 1336040]
Vero C1008	CC₅₀	14.9 μM Compound: 8	Cytotoxicity against African green monkey Vero E6 cells incubated for 72 hrs by MTS assay Cytotoxicity against African green monkey Vero E6 cells incubated for 72 hrs by MTS assay	[PMID: 32845145]
WI-38	IC₅₀	>100 μM Compound: 1, lycorine	Growth inhibition of human WI38 cells after 72 hrs by MTT assay Growth inhibition of human WI38 cells after 72 hrs by MTT assay	[PMID: 19788245]
ZR-75-1	ED₅₀	0.9 μg/mL Compound: 2	Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay	[PMID: 8229016]

In Vitro

Lycorine inhibits cell proliferation in a dose-dependent manner in the abovementioned 4 PCa cell lines, and the IC₅₀ ranged from 5 μM to 10 μM., it also shows Lycorine has little effects on PNT1A cell's proliferation^[1].
SCAP (SREBF chaperone) is an ER-toGolgi transport protein, undergoes a conformational change, and regulates/preserves SREBFs in the ER by forming a complex with INSIG1 (insulin induced gene 1)^[2].
Lycorine (5-40 μM; 16 hours) significantly suppresses SREBFs activity (up to -70%) in a dosedependent manner and does not cause obvious cytotoxicity in cells^[2].
Lycorine (10-20 μM; 2-16 hours) dose- and time-dependently decreases the mature SREBF1 and SREBF2 proteins in HL-7702 cells^[2].
Lycorine (20 μM; 16 hours) neither activates NR1H3 transcription nor affect NR1H3 target genes, including ABCG5? and ABCG8, but Sterols activates NR1H3 transcription activity^[1].
Lycorine (0-25 μM; 48 hours) treatment markedly suppresses the expression of vascular endothelial (VE)-cadherin in a dose-dependent manner and also slightly diminishes the expression of Sema4D in C8161 cells. However, the expression of the other six genes is not affected^[3].
Lycorine (0-25 μM; 48 hours) treatment markedly reduces VE-cadherin protein levels in C8161 cells in a dose-dependent fashion^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

HL-7702/SRE-Luc cells
Concentration:

16 hours
Incubation Time:

5 μM; 10 μM; 20 μM; 40 μM
Result:

Had no cytotoxicity on HL-7702 cells.

Western Blot Analysis^[2]

Cell Line:

HL-7702/SRE-Luc cells
Concentration:

2 hours, 4 hours, 8 hours, 12 hours, 16 hours
Incubation Time:

10 μM; 20 μM
Result:

Decreased p-SREBF1, m-SREBF1, p-SREBF2 and p-SREBF1 protein expression.

RT-PCR^[3]

Cell Line:

C8161 cells
Concentration:

0 μM, 1.56 μM, 3.13 μM, 6.25 μM, 12.5 μM, 25 μM
Incubation Time:

48 hours
Result:

Markedly suppressed the expression of VE-cadherin in a dose-dependent manner and also slightly diminished the expression of Sema4D in C8161 cells.

In Vivo

Lycorine (oral chow; 15 mg/kg, 30 mg/kg; once daily) alleviates fat accumulation and metabolic syndrome, increases lipolysis and betaoxidation of fatty acid along with precursor and mature SREBFs in mice ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

High-fat diet (HFD)-fed C57BL/6J mice^[2]
Dosage:

15 mg/kg, 30 mg/kg
Administration:

Oral chow; once daily
Result:

Ameliorated high-fat diet-induced hyperlipidemia, hepatic steatosis, and insulin resistance in mice.

Chemical Information

CAS No. 476-28-8
Appearance Solid
Masse moléculaire 287.31
Formule C₁₆H₁₇NO₄
Color White to off-white
SMILES

O[C@@H]1[C@@H](O)C=C(CC2)[C@@]3([H])N2CC4=C([C@@]31[H])C=C(OCO5)C5=C4
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
- Alkaloids
- Pyrrole Alkaloids
Initial Source
- Plants
- Amaryllidaceae
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (24)

All WBCell Proliferation/Viability AssayCell Migration/Invasion AssayFlow CytometryIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

J Nanobiotechnology

An oral nanocombinatorial agent exhibits pleiotropic improvement in diabetic nephropathy via modulation of the SCAP/SREBPs pathway. [Abstract]

2026 Mar 22;24(1):405. PMID: 41866523
J Exp Clin Cancer Res

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. [Abstract]

2022 Mar 30;41(1):116. PMID: 35354475

Lycorine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Mar 30;41(1):116. [Abstract]

Immunoblot analysis of SCAP protein expression at different concentrations. PLC-SR cells (control) were treated with Lycorine (Ly) (1, 2, 4 μM) alone, Sorafenib (Sora) alone or a combination of Lycorine and Sorafenib (Ly + Sora).

Lycorine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Mar 30;41(1):116. [Abstract]

The combined use of Lycorine (1, 2, 4 μM) and Sorafenib significantly inhibited the proliferation of PLC-SR cells.

Lycorine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Mar 30;41(1):116. [Abstract]

Lycorine (1, 2, 4 μM) combined with Sorafenib decelerated the migration and invasion of sorafenib-resistant HCC cells.

Lycorine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Mar 30;41(1):116. [Abstract]

Flow cytometry analysis indicated that when Lycorine (1, 2, 4 μM) was combined with Sorafenib, the percentage of S phase cells was decreased, and apoptosis was significantly increased.

Lycorine purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2022 Mar 30;41(1):116. [Abstract]

Lycorine (10 mg/kg, i.g.) combined with Sorafenib can reduce the tumor volume in mice.
Pharmacol Res

Lycorine improves peripheral nerve function by promoting Schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy. [Abstract]

2022 Jan:175:105985. PMID: 34863821
Int J Mol Med

Lycorine upregulates the expression of RMB10, promotes apoptosis and inhibits the proliferation and migration of cervical cancer cells. [Abstract]

2022 Dec;50(6):145. PMID: 36367172
Eur J Pharmacol

Lycorine eliminates B-cell acute lymphoblastic leukemia cells by targeting PSAT1 through the serine/glycine metabolic pathway. [Abstract]

2023 Dec 15:961:176162. PMID: 37951487
Int J Mol Sci

Lycorine Inhibits Influenza Virus Replication by Affecting Nascent Nucleoporin Nup93 Synthesis. [Abstract]

2025 Jun 3;26(11):5358. PMID: 40508167
Mol Med Rep

Excess phosphate promotes SARS‑CoV‑2 N protein‑induced NLRP3 inflammasome activation via the SCAP‑SREBP2 signaling pathway. [Abstract]

2024 Mar;29(3):48. PMID: 38275129
J Mol Cell Cardiol

Lycorine hydrochloride reveals a novel role in preventing neointimal hyperplasia through MAPK-mediated phenotypic switching of smooth muscle cells. [Abstract]

2026 Apr 28:S0022-2828(26)00059-3. PMID: 42061807
Cancers (Basel)

Lycorine hydrochloride Suppresses the Proliferation and Invasion of Esophageal Cancer by Targeting TRIM22 and Inhibiting the JAK2/STAT3 and Erk Pathways. [Abstract]

2025 Feb 20;17(5):718. PMID: 40075566
Microorganisms

Screening of Endophytic Bacteria of Leucojum aestivum 'Gravety Giant' as a Potential Source of Alkaloids and as Antagonist to Some Plant Fungal Pathogens. [Abstract]

2022 Oct 21;10(10):2089. PMID: 36296365
Antiviral Res

Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library. [Abstract]

2024 Jul 2:228:105955. PMID: 38964614
Pest Manag Sci

Functional analysis of down-regulated CYP6AE gene clusters involved in the insecticidal mechanism of lycorine against Spodoptera litura. [Abstract]

2026 Jun 20. PMID: 42322590
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
J Nat Med

A plant alkaloid lycorine inhibits non-small cell lung cancer cell proliferation, metastasis, glycolysis and promotes ferroptosis through the ZNF143/SPC25 axis. [Abstract]

2026 Mar 9. PMID: 41801295
Ann Hematol

Lycorine inhibits the proliferation of acute myeloid leukemia cells by upregulating the expression of THBS1. [Abstract]

2026 Jan 17;105(1):24. PMID: 41545705
Ann Hematol

Lycorine induces apoptosis of acute myeloid leukemia cells and inhibits triglyceride production via binding and targeting FABP5. [Abstract]

2023 May;102(5):1073-1086. PMID: 36943465
Oncol Lett

Ferroptosis is involved in the anti-tumor effect of lycorine in renal cell carcinoma cells. [Abstract]

2021 Nov;22(5):781. PMID: 34594422
Mol Biol

2026 Jan 20.
SSRN

2025 Dec 19.
Preprints

2024 Nov.
bioRxiv

A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer's disease. [Abstract]

2024 Feb 6:2024.02.06.579103. PMID: 38370689
Patent

US20230014181.
Research Square Preprint

2022 Feb.
Research Square Preprint

2022 Jan.

Solvant et solubilité

In Vitro:

DMSO : 25 mg/mL (87.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4806 mL

17.4028 mL

34.8056 mL

5 mM

0.6961 mL

3.4806 mL

6.9611 mL

10 mM

0.3481 mL

1.7403 mL

3.4806 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (87.01 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Hu M, et al.Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.Oncotarget. 2015 Jun 20;6(17):15348-61.

[2]. Zu-Guo Zheng, et al. Discovery of a Potent SCAP Degrader That Ameliorates HFD-induced Obesity, Hyperlipidemia and Insulin Resistance via an Autophagy-Independent Lysosomal Pathway. Autophagy. 2020 May 20;1-22. [Content Brief]

[3]. [1].Liu, R. et al. Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. Pigment cell & melanoma research 25, 630-638, doi:10.1111/j.1755-148X.2012.01036.x (2012). [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4806 mL	17.4028 mL	34.8056 mL	87.0140 mL
	5 mM	0.6961 mL	3.4806 mL	6.9611 mL	17.4028 mL
	10 mM	0.3481 mL	1.7403 mL	3.4806 mL	8.7014 mL
	15 mM	0.2320 mL	1.1602 mL	2.3204 mL	5.8009 mL
	20 mM	0.1740 mL	0.8701 mL	1.7403 mL	4.3507 mL
	25 mM	0.1392 mL	0.6961 mL	1.3922 mL	3.4806 mL
	30 mM	0.1160 mL	0.5801 mL	1.1602 mL	2.9005 mL
	40 mM	0.0870 mL	0.4351 mL	0.8701 mL	2.1754 mL
	50 mM	0.0696 mL	0.3481 mL	0.6961 mL	1.7403 mL
	60 mM	0.0580 mL	0.2900 mL	0.5801 mL	1.4502 mL
	80 mM	0.0435 mL	0.2175 mL	0.4351 mL	1.0877 mL

Lycorine

24 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Lycorine

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Antibacterial Compound Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Anti-Cancer Natural Product Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) Lycorine

Activité biologique

Chemical Information

Publications (24)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Lycorine Related Classifications

HY-N0288 Related Classifications